Oxford Cancer Biomarkers Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- Investors
-
11
Oxford Cancer Biomarkers General Information
Description
Developer of predictive biomarker diagnostic tests designed to advance personalized medicine within oncology, colorectal cancer and its treatments. The company's tests indicate dihydropyridine dehydrogenase deficiency and variants detected strongly associated with partial dihydropyrimidine deficiency as well as the increased risk of toxicity grades, enabling doctors and patients to examine resected tissue samples and identify the risk of relapse before it happens.
Contact Information
Website
www.oxfordbio.comCorporate Office
- C/o Douglas Mcdonald Ca
- 2 Octavia Buildings
- Kilmacolm PA13 4AE
- Scotland, United Kingdom
Corporate Office
- C/o Douglas Mcdonald Ca
- 2 Octavia Buildings
- Kilmacolm PA13 4AE
- Scotland, United Kingdom
Oxford Cancer Biomarkers Timeline
Oxford Cancer Biomarkers Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC | 03-Apr-2023 | Completed | Generating Revenue | |||
| 10. Grant | 03-Mar-2023 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 03-Jun-2019 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 29-May-2019 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 08-May-2017 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 15-Nov-2016 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 14-Dec-2015 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 01-Jan-2013 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 18-Jan-2012 | $4.65M | $4.65M | Completed | Startup | |
| 2. Early Stage VC | 01-Jan-2011 | Completed | Startup |
Oxford Cancer Biomarkers Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 4,972 | $1.287292 | $233 | $233 | 1x | $233 | 33.75% | |
| Ordinary | 759 | $1.287292 | $5088.11 | $5088.11 | 1x | $5088.11 | 5.15% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Oxford Cancer Biomarkers Patents
Oxford Cancer Biomarkers Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4645338-A1 | Histopathology-based solid tumour analysis | Inactive | 03-May-2024 | ||
| GB-202406267-D0 | Histopathology-based solid tumour analysis | Pending | 03-May-2024 | ||
| GB-2640747-A | Histopathology-based solid tumour analysis | Pending | 03-May-2024 | ||
| US-20250342974-A1 | Histopathology-based solid tumour analysis | Pending | 03-May-2024 | ||
| EP-3271864-A1 | Tissue sample analysis technique | Active | 18-Mar-2015 | A61B10/0241 |
Oxford Cancer Biomarkers Signals
Oxford Cancer Biomarkers Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Panacea Capital | Venture Capital | Minority | ||
| NHS England | Government | |||
| Kwang Dong Pharmaceutical | Corporation | Minority | ||
| Plutus Investment Group | Family Office | Minority |
Oxford Cancer Biomarkers FAQs
-
When was Oxford Cancer Biomarkers founded?
Oxford Cancer Biomarkers was founded in 2010.
-
Where is Oxford Cancer Biomarkers headquartered?
Oxford Cancer Biomarkers is headquartered in Kilmacolm, United Kingdom.
-
What is the size of Oxford Cancer Biomarkers?
Oxford Cancer Biomarkers has 6 total employees.
-
What industry is Oxford Cancer Biomarkers in?
Oxford Cancer Biomarkers’s primary industry is Discovery Tools (Healthcare).
-
Is Oxford Cancer Biomarkers a private or public company?
Oxford Cancer Biomarkers is a Private company.
-
What is Oxford Cancer Biomarkers’s current revenue?
The current revenue for Oxford Cancer Biomarkers is .
-
How much funding has Oxford Cancer Biomarkers raised over time?
Oxford Cancer Biomarkers has raised $23.4M.
-
Who are Oxford Cancer Biomarkers’s investors?
, Panacea Capital, NHS England, Kwang Dong Pharmaceutical, and Plutus Investment Group are 5 of 11 investors who have invested in Oxford Cancer Biomarkers.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process